News + Filings Transactions
|
Chang Carmen
| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 08/11/2023 | Bright Health Group Inc. | BHG | Purchase | Warrant (Right to Buy) | 828.4k | $0.01 | $8.3k | See Note 3 | 08/11/2023 |
| 07/17/2023 | Savara Inc | SVRA | Purchase | Common Stock | 333.3k | $3.00 | $1000k | See Note 2 | 07/17/2023 |
| 05/24/2023 | Coursera, Inc. | COUR | Grant | Common Stock | 16.2k | $0.00 | $0 | | 05/24/2023 |
| 03/15/2023 | Coursera, Inc. | COUR | Sale | Common Stock | 1.2k | $11.82 | $14.5k | | 03/15/2023 |
| 11/30/2022 | Akouos, Inc. | AKUS | Other | Common Stock | 4.3M | $0.00 | $0 | See Note 3 | 11/30/2022 |
| 05/25/2022 | GENOCEA BIOSCIENCES, INC. | GNCA | Sale | Common Stock | 4.4M | $0.08 | $362.7k | See Note 2 | 05/24/2022 |
| 05/24/2022 | GENOCEA BIOSCIENCES, INC. | GNCA | Sale | Common Stock | 5.9M | $0.07 | $387.9k | See Note 2 | 05/24/2022 |
| 05/13/2022 | Coursera, Inc. | COUR | Grant | Common Stock | 8.7k | $0.00 | $0 | | 05/13/2022 |
| 04/11/2022 | Trevi Therapeutics, Inc. | TRVI | Purchase | Common Stock | 2.6M | $1.90 | $5M | See Note 2 | 04/11/2022 |
| 04/11/2022 | Trevi Therapeutics, Inc. | TRVI | Purchase | Common Stock | 948.9k | $1.90 | $1.8M | See Note 3 | 04/11/2022 |
| 04/11/2022 | Trevi Therapeutics, Inc. | TRVI | Purchase | Pre-Funded Warrants | 3M | $0.00 | $3k | See Note 3 | 04/11/2022 |
| 01/03/2022 | Bright Health Group Inc. | BHG | Purchase | Series A Convertible Perpetual Preferred Stock | 75k | $1,000.00 | $75M | See Note 4 | 01/03/2022 |
| 01/03/2022 | Bright Health Group Inc. | BHG | Purchase | Series A Convertible Perpetual Preferred Stock | 125k | $1,000.00 | $125M | See Note 5 | 01/03/2022 |
| 12/22/2021 | Metacrine, Inc. | MTCR | Sale | Common Stock | 170.9k | $0.91 | $155.6k | See Note 1 | 12/10/2021 |
| 12/22/2021 | Metacrine, Inc. | MTCR | Sale | Common Stock | 288.8k | $1.00 | $289.3k | See Note 1 | 12/10/2021 |
| 12/10/2021 | Metacrine, Inc. | MTCR | Sale | Common Stock | 37.6k | $1.32 | $49.6k | See Note 1 | 12/10/2021 |
| 11/01/2021 | Coursera, Inc. | COUR | Grant | Common Stock | 23k | $0.00 | $0 | | 11/01/2021 |
| 10/18/2021 | Trevi Therapeutics, Inc. | TRVI | Purchase | Common Stock | 1.9M | $0.00 | $0 | See Note 2 | 10/18/2021 |
| 10/18/2021 | Trevi Therapeutics, Inc. | TRVI | Purchase | 7-Year Common Stock Warrant | 1.9M | $1.37 | $2.5M | See Note 2 | 10/18/2021 |
| 06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Common Stock | 2.7M | $0.00 | $0 | See Note 2 | 06/28/2021 |
| 06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Common Stock | 3.3M | $0.00 | $0 | See Note 2 | 06/28/2021 |
| 06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Common Stock | 669k | $0.00 | $0 | See Note 2 | 06/28/2021 |
| 06/28/2021 | Monte Rosa Therapeutics, Inc. | | Purchase | Common Stock | 1M | $19.00 | $20M | See Note 2 | 06/28/2021 |
| 06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Series A-2 convertible preferred stock | 9.6M | $0.00 | $0 | See Note 2 | 06/28/2021 |
| 06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Series B convertible preferred stock | 11.5M | $0.00 | $0 | See Note 2 | 06/28/2021 |
| 06/28/2021 | Monte Rosa Therapeutics, Inc. | | Conversion | Series C convertible preferred Stock | 2.4M | $0.00 | $0 | See Note 2 | 06/28/2021 |
| 03/16/2021 | Marker Therapeutics, Inc. | MRKR | Purchase | Common Stock | 5.7M | $1.75 | $10M | See Note 1 | 03/16/2021 |
| 12/04/2020 | Regulus Therapeutics Inc. | RGLS | Purchase | Class A-3 Convertible Preferred Stock | 258.7k | $6.22 | $1.6M | See Note 2 | 12/04/2020 |
| 12/04/2020 | Regulus Therapeutics Inc. | RGLS | Purchase | Common Stock Purchase Warrant (right to buy) | 5.2M | $0.75 | $3.9M | See Note 2 | 12/04/2020 |
| 12/04/2020 | Regulus Therapeutics Inc. | RGLS | Purchase | Common Stock | 4.4M | $0.62 | $2.7M | See Note 2 | 12/04/2020 |
| 09/18/2020 | Metacrine, Inc. | MTCR | Conversion | Series C Convertible Preferred Stock | 333k | $0.00 | $0 | See footnote 2 | 09/18/2020 |
| 09/18/2020 | Metacrine, Inc. | MTCR | Conversion | Series B Convertible Preferred Stock | 2M | $0.00 | $0 | See footnote 2 | 09/18/2020 |
| 09/18/2020 | Metacrine, Inc. | MTCR | Purchase | Common Stock | 769.2k | $13.00 | $10M | See footnote 2 | 09/18/2020 |
| 09/18/2020 | Metacrine, Inc. | MTCR | Conversion | Common Stock | 333k | $0.00 | $0 | See footnote 2 | 09/18/2020 |
| 09/18/2020 | Metacrine, Inc. | MTCR | Conversion | Common Stock | 2M | $0.00 | $0 | See footnote 2 | 09/18/2020 |
|
|